289 patents
Page 4 of 15
Utility
Pediatric Formulations for Treatment of Cancer
22 Dec 22
Provided herein are pediatric formulations comprising 2 methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, and methods for treating, preventing and managing cancer using the same.
Biplob K. MITRA, Alex J. AYCINENA, Alfred C.F. RUMONDOR
Filed: 13 Nov 20
Utility
Combination therapy for the treatment of cancer
20 Dec 22
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab.
Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
Filed: 30 Sep 19
Utility
Treatment of immune-related and inflammatory diseases
13 Dec 22
Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases.
Peter H. Schafer, Ying Ye, Donna J. Sutherland, Rajesh Chopra, Anita Gandhi
Filed: 2 Sep 20
Utility
Methods of Treatment with N-((R)-1-(3-CHLOROPYRIDIN-2-YL)-2,2,2-TRIFLUOROETHYL)-2-((S)-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLINE-5-CARBOXAMIDE
8 Dec 22
Provided herein are methods of treating, preventing, managing, and/or ameliorating acute myeloid leukemia or myelodysplastic syndrome comprising administering N-((R)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
Michael POURDEHNAD
Filed: 5 May 22
Utility
Antiproliferative Compounds and Methods of Use Thereof
8 Dec 22
Compounds of formula I for treating, preventing or managing cancer are disclosed.
Brian E. Cathers, Matthew Daniel Correa, Joshua Hansen, Ehab M. Khalil, Antonia Lopez-Girona, Kyle MacBeth, Hon-Wah Man, George W. Muller, Michael Pourdehnad, Raj Raheja
Filed: 23 Dec 21
Utility
Use of Biomarkers to Predict Clinical Sensitivity to 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
8 Dec 22
A method of identifying a subject having cancer who is likely to be responsive to a treatment comprising a compound or predicting the responsiveness of a subject having or suspected of having cancer to a treatment comprising the compound, comprising: providing a sample from the subject; measuring gene expression level of one or more genes in the sample; and identifying the subject as being likely to be responsive to the treatment comprising the compound if the expression level of the gene is different from a reference level, and wherein the gene is a gene involved in mTOR signaling, or the gene is ILF 2 or ILFS.
Gang LU, Christine SURKA
Filed: 27 Oct 20
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
6 Dec 22
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate.
Jerry Lee Atwood
Filed: 9 Sep 20
Utility
Methods for Treating Leukemia and Use of a Leukemic Stem Cell Signature to Predict Clinical Sensitivity to Therapies
1 Dec 22
Provided herein are methods of using certain biomarkers, such as gene sets (e.g., a leukemic stem cell (LSC) signature), in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancer (e.g, lymphoma, multiple myeloma (MM), and leukemia, such as acute myeloid leukemia (AML)).
Michael POURDEHNAD, Kyle James MACBETH, Daniel Weston PIERCE, Remco Gerard LOOS, Jinhong FAN
Filed: 27 Oct 20
Utility
Cereblon-based Heterodimerizable Chimeric Antigen Receptors
24 Nov 22
Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.
Shuichan XU
Filed: 6 May 22
Utility
Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
22 Nov 22
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Sreenivas S. Bhat, Fabien Boulineau, Donna Carroll, Tracy Lee Gaebele, Yuchuan Gong, Isabel Minjung Hong, Zhengmao Li, Ye Tian
Filed: 20 Oct 20
Utility
Processes for the preparation of (S)-tert-butyl 4,5- diamino-5-oxopentanoate
22 Nov 22
Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof.
John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
Filed: 5 Jun 20
Utility
Heterocyclic compounds and their use for treatment of helminthic infections and diseases
22 Nov 22
Natalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
Filed: 24 Apr 20
Utility
Methods of Treating Non-hodgkin Lymphoma Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
17 Nov 22
Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.
Tonia J. Buchholz, Michael Pourdehnad, Poliana Alves Patah, Fan Wu
Filed: 20 Apr 22
Utility
Combination Therapies Comprising Apremilast and TYK2 Inhibitors
27 Oct 22
Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject.
Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
Filed: 9 May 22
Utility
Engineering of an Antibody for Tumor-selective Binding of CD47
27 Oct 22
Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.
Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Henry CHAN, Kandasamy HARIHARAN, Ho CHO
Filed: 3 Apr 20
Utility
Activin-ActRII antagonists and uses for treating anemia
18 Oct 22
Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
Filed: 3 Dec 15
Utility
Tablet Compositions
13 Oct 22
Provided herein is a tablet comprising 2-methyl-1-[(4-[-6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.
Sreenivas S. Bhat, Scott Burnside, Darshan Parikh, Chong-Hui Gu, Syed Altaf
Filed: 21 Jun 22
Utility
Anti-bcma Antibody Conjugate, Compositions Comprising the Same, and Methods of Making and Using the Same
13 Oct 22
The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions.
John LEE, Ryan STAFFORD, Alice YAM, Xiaofan LI, Abigail YU, Amandeep GAKHAL
Filed: 1 May 20
Utility
Methods of Treating Non-hodgkin Lymphoma Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
13 Oct 22
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Filed: 24 Jun 22
Utility
Bcma-binding Antibodies and Uses Thereof
13 Oct 22
Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
Filed: 17 Jun 22